Strong Year For Cephalon, But An Uncertain Future Remains
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma has made plenty of acquisitions and is pursuing late-stage options, but the upcoming loss of its lead product to generic competition may not be filled by the risky pipeline.